17412-19-0

Basic information

• Product Name: 6-chloro-7-methylimidazo[1,2-b]pyridazine
• CAS NO: 17412-19-0
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.5956
• Mol File: 17412-19-0.mol
• Article Data: 9

Chemical Properties

• Density: 1.436g/cm³
• Refractive Index: 1.681
• CAS DataBase Reference: 6-chloro-7-methylimidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-7-methylimidazo[1,2-b]pyridazine(17412-19-0)
• EPA Substance Registry System: 6-chloro-7-methylimidazo[1,2-b]pyridazine(17412-19-0)

Safety Data

• Hazardous Substances Data: 17412-19-0(Hazardous Substances Data)

Upstream product

• 107-20-0 2-chloroethanal 
• 66346-87-0 6-chloro-5-methylpyridazin-3-amine 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 64068-00-4 3-amino-6-chloro-4-methylpyridazine 

Downstream Products

• 1025066-16-3 3-bromo-6-chloro-7-methyl-imidazo[1,2-b]pyridazine 
• 1150567-11-5 N-(3,4-dichlorobenzyl)-7-methylimidazo[1,2-b]pyridazin-6-amine 

Relevant articles and documents

COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5

Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substa

SUBSTITUTED AMINOIMIDAZOPYRIDAZINES

The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comp

HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES

The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.